waixenicin A

a TRPM7 channel inhibitor with antineoplastic activity; isolated from the soft coral Sarcothelia edmondsoni; structure in first source

Networked: 9 relevant articles (1 outcomes, 2 trials/studies)

1.	Brain Injuries (Brain Injury) 01/01/2021 - "In vivo, we found a significant reduction of brain injury and improvement of short- and long-term functional outcomes after HI after administration of specific TRPM7 blocker waixenicin A. " 12/01/2020 - "Most recently, we found that waixenicin A reduced hypoxic-ischemic brain injury and preserved long-term behavioral outcomes in mouse neonates. "
2.	Colonic Neoplasms (Colon Cancer) 01/01/2017 - "Early stage colon cancer proceeds independent of systemic Mg2+ status and TRPM7, and waixenicin A is a useful pharmacological tool to study of TRPM7 in vitro and in vivo."
3.	Adenocarcinoma 02/01/2013 - "The aim of this study was to clarify the role for TRPM7 channels and the effect of waixenicin A on the pacemaking activity of interstitial cells of Cajal (ICCs) and on the cell viability of the human gastric and breast adenocarcinoma cell lines, AGS and MCF-7, respectively. "
4.	Hypoxia (Hypoxemia) 02/01/2023 - "On the other hand, long-term hypoxia caused a progressive retraction of axons and dendrites that could be attenuated by the TRPM7-specific inhibitor waixenicin A. " 01/01/2019 - "Moreover, waixenicin A exacerbated hypoxia-induced PAH features in rats. "
5.	Aberrant Crypt Foci 01/01/2017 - "However, neither waixenicin A, nor a diet low in Mg2+, affect aberrant crypt foci development in an azoxymethane-induced colorectal cancer mouse model. "

1.	Azoxymethane